Last updated: February 15, 2026
The drug identified by NDC 00406-5771 is Xyosted (testosterone enanthate), a prescription hormone therapy indicated for testosterone replacement therapy (TRT) in adult males with hypogonadism. The following analysis covers the current market landscape, competitive positioning, regulatory environment, and price trends.
Market Landscape and Demand Drivers
Indication and Patient Population
- Testosterone deficiency affects approximately 3 to 4 million men in the U.S., with a rising detection rate due to increased awareness and screening.
- Xyosted addresses the need for long-acting testosterone administration, an alternative to intramuscular injections and topical gels.
Product Formulation and Advantages
- Xyosted is administered via subcutaneous injection, typically once weekly or every two weeks, improving compliance versus daily topical treatments or more frequent injections.
- Its formulation allows for stable testosterone levels, reducing fluctuations associated with other administration methods.
Competitive Landscape
| Product |
Formulation |
Dosing Frequency |
Market Share (2022) |
List Price (approx.) |
| Xyosted (testosterone enanthate) |
Subcutaneous injection |
Weekly/biweekly |
Emerging, 10-15% |
~$380 per syringe (200 mg/1 mL) |
| AndroGel (topical) |
Gel |
Daily |
30-35% |
~$650 per 4.5 g tube |
| Depo-Testosterone (IM) |
Intramuscular injection |
Every 2-4 weeks |
25-30% |
~$70 per 100 mg/ml injection |
| Testopel (pellet implant) |
Subcutaneous pellet |
Every 3-6 months |
10% |
~$1,400 per implantation |
Xyosted's market share remains limited but is growing as physicians seek long-acting, subcutaneous options that reduce compliance issues tied to gels and injections.
Regulatory Environment
- FDA approval received in 2014 for adult male hypogonadism.
- Market expansion in other regions, including Europe and Canada, includes approvals or ongoing reviews.
- Continued updates to testosterone therapy guidelines recommend individualized treatment plans, influencing prescribing patterns for long-acting injectables like Xyosted.
Pricing Trends and Projections
Current Price Point
- Typical list price: approximately $380 per syringe (200 mg/1 ml).
- Average monthly cost: roughly $380 to $760, depending on dosing frequency.
- Insurance, rebates, and patient assistance programs significantly influence out-of-pocket costs.
Market Trends
- Injectable testosterone therapies have generally maintained stable prices over the past five years, with slight fluctuations driven by manufacturing costs and competitive pressures.
- The shift toward long-acting formulations like Xyosted is expected to sustain demand and stabilize pricing, given their convenience advantage.
- Competition from biosimilars and compounded formulations may exert downward pressure, but patent protection until approximately 2030 limits immediate generic erosion.
Projection (Next 3-5 Years)
- Price stability is expected in the absence of major regulatory or patent challenges.
- Average monthly expenditure for the drug could range between $700–$850, factoring in potential formulary negotiations.
- Introduction of biosimilars or licensed generics might lower prices by 10-15% within the next 3 years.
Key Factors Influencing Future Pricing
- Regulatory decisions and patent litigation will impact generic availability.
- Insurance formulary placement can alter patient access and out-of-pocket costs.
- Market penetration rates depend on physician acceptance and patient preference.
- Emerging competitors with alternative delivery systems might challenge Xyosted's market share.
Summary
| Aspect |
Details |
| Estimated market size |
$2 billion globally; growing with aging populations |
| Current price range |
~$380 per syringe; monthly costs ~$700–$850 |
| Market trend |
Stable prices; growth driven by convenience and compliance benefits |
| Competition |
Gels, injections, implants; biosimilars expected in late 2020s |
Key Takeaways
- Xyosted's niche as a long-acting subcutaneous testosterone therapy positions it favorably amid rising demand for convenient TRT options.
- Price stability is expected over the next five years, with modest declines possible due to increased competition.
- Market growth will hinge on prescriber adoption, payer coverage policies, and regulatory dynamics.
- Cost considerations remain significant for patient access, but competitive advantages include dosing frequency and ease of administration.
FAQs
-
How does Xyosted compare price-wise with other testosterone therapies?
It is priced higher than injectable testosterone solutions like Depo-Testosterone but lower than pellet implants. Its weekly or biweekly dosing offers convenience that can justify the cost difference.
-
What factors could lead to price reductions for Xyosted?
Introduction of biosimilars, patent expiry, increased market competition, and formulary negotiations.
-
Is insurance coverage widely available for Xyosted?
Coverage varies; rebates and patient assistance programs mitigate out-of-pocket costs for many patients.
-
What is the primary driver for Xyosted's market growth?
Preference for long-acting, convenient formulations that improve treatment adherence.
-
Are there upcoming regulatory challenges for this product?
No current challenges; patent protection extends until approximately 2030, maintaining exclusivity.
Citations
[1] IQVIA, "U.S. Prescription Drug Market Data," 2022.
[2] FDA, "Xyosted (testosterone enanthate) Label," 2014.
[3] Evaluate Pharma, "Global Testosterone Market Review," 2022.
